28.06.2024 13:20:06
|
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
The European Commission is expected to announce a final decision in the coming months. FL and DLBCL are the two most common subtypes of B-cell non-Hodgkin lymphoma (B-NHL).
The positive CHMP opinion is supported by results from the Phase 1 ELM-1 and pivotal Phase 2 ELM-2 trials, which demonstrated robust, durable response rates and an acceptable safety profile of odronextamab in adults with R/R FL or R/R DLBCL. The EMA previously granted odronextamab Orphan Designation for both FL and DLBCL. Odronextamab is currently under clinical development and has not been approved by any regulatory authority.
Regeneron continues to evaluate the use of odronextamab as a monotherapy and in combination across earlier lines of therapy in challenging-to-treat lymphomas.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Regeneron Pharmaceuticals Inc.mehr Nachrichten
17.12.24 |
Handel in New York: NASDAQ 100 gibt am Nachmittag nach (finanzen.at) | |
17.12.24 |
NASDAQ 100 aktuell: NASDAQ 100 fällt am Dienstagmittag zurück (finanzen.at) | |
12.12.24 |
Börse New York: NASDAQ 100 schwächelt zum Ende des Donnerstagshandels (finanzen.at) | |
12.12.24 |
Schwacher Handel in New York: NASDAQ 100 verliert am Donnerstagnachmittag (finanzen.at) | |
12.12.24 |
Zurückhaltung in New York: NASDAQ 100 fällt am Mittag (finanzen.at) | |
11.12.24 |
NASDAQ Composite Index-Wert Regeneron Pharmaceuticals-Aktie: So viel Gewinn hätte eine Regeneron Pharmaceuticals-Investition von vor 3 Jahren eingebracht (finanzen.at) | |
05.12.24 |
Zurückhaltung in New York: NASDAQ 100 zum Ende des Donnerstagshandels im Minus (finanzen.at) | |
04.12.24 |
NASDAQ Composite Index-Titel Regeneron Pharmaceuticals-Aktie: So viel Verlust hätte eine Regeneron Pharmaceuticals-Investition von vor einem Jahr eingebracht (finanzen.at) |